FindTrial
Sign In

CMP-001

DRUG11 trials

Sponsors

Pfizer, Regeneron Pharmaceuticals, Sheba Medical Center, Diwakar Davar, Umar Farooq

Conditions

Advanced CancerAdvanced MelanomaColorectal Neoplasms MalignantLiver MetastasesLymph Node CancerLymphomaMalignant MelanomaMelanoma

Phase 1

A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)
TerminatedNCT02554812
PfizerAdvanced Cancer
Start: 2015-11-09End: 2023-03-23Updated: 2024-07-30
Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy
CompletedNCT02680184
Regeneron PharmaceuticalsMelanoma
Start: 2016-04-12End: 2022-12-06Updated: 2025-07-04
Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Participants With Advanced Melanoma
CompletedNCT03084640
Regeneron PharmaceuticalsMalignant Melanoma
Start: 2017-05-04End: 2021-09-30Updated: 2022-08-03
Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer
CompletedNCT03438318
Regeneron PharmaceuticalsNon Small Cell Lung Cancer
Start: 2018-03-15End: 2019-12-11Updated: 2022-08-03
Combined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer
CompletedNCT03507699
Sheba Medical CenterColorectal Neoplasms Malignant, Liver Metastases
Start: 2018-12-15End: 2022-05-25Updated: 2023-04-18
CMP-001 for Relapsed and Refractory Lymphoma
TerminatedNCT03983668
Umar FarooqLymphoma
Start: 2020-01-31End: 2025-04-08Updated: 2026-03-30

Phase 2

CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease
CompletedNCT03618641
Diwakar DavarLymph Node Cancer, Melanoma
Start: 2018-08-08End: 2023-12-31Updated: 2025-05-14
CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
TerminatedNCT04633278
Regeneron PharmaceuticalsSquamous Cell Carcinoma of Head and Neck
Start: 2021-01-21End: 2024-01-19Updated: 2025-05-11
CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma
TerminatedNCT04695977
Regeneron PharmaceuticalsAdvanced Melanoma, Melanoma, Metastatic Melanoma +1
Start: 2021-02-24End: 2024-07-22Updated: 2025-09-05
CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma
TerminatedNCT04698187
Regeneron PharmaceuticalsAdvanced Melanoma, Melanoma, Metastatic Melanoma +1
Start: 2021-03-11End: 2024-02-05Updated: 2025-06-11
CMP-001 and Pre-operative Stereotactic Body Radiation Therapy (SBRT) in Early Stage Triple Negative Breast Cancer (TNBC)
Active, not recruitingNCT04807192
Centre Hospitalier Universitaire VaudoisTriple Negative Breast Cancer
Start: 2021-04-07End: 2027-12-31Target: 40Updated: 2025-02-27

Related Papers

Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial
Cancer Cell2024-10-3136 citations
Cryoablation and post-progression immune checkpoint inhibition in metastatic melanoma: a phase II trial.
2024-08-276 citations
Phase Ib/II Study of Lacnotuzumab in Combination with Spartalizumab in Patients with Advanced Malignancies
Journal of Immunotherapy and Precision Oncology2023-11-249 citations
Abstract 3270: The XernaTM TME Panel potentially predicts response to a combination of the TLR9 agonist vidutolimod and PD-1 inhibitor pembrolizumab in metastatic melanomas with prior anti-PD-1 treatment
Cancer Research2023-04-04
Combination treatment of intratumoral vidutolimod (CMP-001), radiosurgery, nivolumab, and ipilimumab for metastatic colorectal carcinoma.
Journal of Clinical Oncology2023-01-243 citations
605 Neoadjuvant vidutolimod (vidu) and nivolumab (nivo) results in MPR and immune activation in high-risk resectable melanoma (MEL): final phase II clinical trial results
Regular and Young Investigator Award Abstracts2022-11-014 citations
Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade-Resistant Advanced NSCLC.
2022-10-267 citations
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors
Journal for ImmunoTherapy of Cancer2022-10-0152 citations
Abstract LB107: Novel transcriptional signatures associated with antitumor activity in vidutolimod (vidu)-treated patients (pts) with anti-PD-1-refractory melanoma and non-small cell lung cancer (NSCLC)
Cancer Research2022-06-151 citations
Preliminary results from an early phase trial of in situ immunization of lymphoma with a virus likeparticle containing a TLR9 agonist combined with anti-PD1 therapy (NCT03983668).
Journal of Clinical Oncology2022-06-01
950 Final analysis: phase 1b study investigating intratumoral injection of toll-like receptor 9 agonist vidutolimod ± pembrolizumab in patients with PD-1 blockade–refractory melanoma
2021-11-0110 citations
Abstract CT032: CMP-001 demonstrates improved response in noninflamed anti-PD-1 refractory melanoma and response is associated with serum CXCL10
Cancer Research2021-07-015 citations
CMP-001-007: Open-label, phase 2 study of intratumoral CMP-001 + pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma.
Journal of Clinical Oncology2021-05-203 citations
304 Intratumoral injection of CMP-001, a toll-like receptor 9 (TLR9) agonist, in combination with pembrolizumab reversed programmed death receptor 1 (PD-1) blockade resistance in advanced melanoma
Regular and Young Investigator Award Abstracts2020-11-0131 citations
303 Phase II trial of neoadjuvant nivolumab (Nivo) and intra-tumoral (IT) CMP-001 in high-risk resectable melanoma (Neo-C-Nivo): final results
Regular and Young Investigator Award Abstracts2020-11-0123 citations
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.
2017-10-23590 citations
Avelumab (MSB0010718C; anti-PD-L1) in combination with other cancer immunotherapies in patients with advanced malignancies: The phase 1b/2 JAVELIN Medley study.
Journal of Clinical Oncology2016-05-208 citations
Phase Ib trial of the CpG-A Oligonucleotide CMP-001 combined with pembrolizumab (Pembro) in patients with advanced melanoma.
Journal of Clinical Oncology2016-05-203 citations